TNF-α抑制剂在炎症性肠病治疗中的应用  

The application of TNF-α in the treatment of inflammatory bowel disease

作　　者：高娴[1] 

机构地区：[1]中国人民解放军92676部队医院门诊部特诊科

出　　处：《转化医学电子杂志》2016年第7期90-91,共2页E-Journal of Translational Medicine

基　　金：四川省卫生厅项目(130419)

摘　　要：TNF-α作为治疗包括炎症性肠病在内的炎症紊乱性疾病的治疗靶标已被广泛接受.TNF-α抑制剂英夫利昔单抗、阿达木单抗、戈利木单抗以及聚乙二醇结合赛妥珠单抗均已由FDA批准用于IBD的治疗.因此,深入了解TNF-α单克隆抗体的作用机制以及安全有效的用于IBD的治疗将为IBD患者带来更多获益.TNF-α has been widely accepted as a therapeutic targetfor inflammatory disorders including inflammatory bowel disease.TNF-α inhibitors monoclonal antibodies including infliximab, adalimumab, golimumab, and certolizumabpegol had beenapproved by FDA for the treatment of IBD. IBD patients will benefitfrom a more thorough understanding of the mechanism of TNFolmonoclonal antibodies and the development of safe and effectivestrategies to IBD treatment.

关 键 词：TNF-Α 炎症性肠病 单克隆抗体 

分 类 号：R574[医药卫生—消化系统]